| Veeda O Landeras, MD | |
|
2740 W Foster Ave Ste 207, Chicago, IL 60625-3526 | |
| (773) 820-8502 | |
| (773) 716-3712 |
| Full Name | Veeda O Landeras |
|---|---|
| Gender | Female |
| Speciality | Nephrology |
| Experience | 26 Years |
| Location | 2740 W Foster Ave Ste 207, Chicago, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306045646 | NPI | - | NPPES |
| 036144328 | Medicaid | IL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 036144328 (Illinois) | Primary |
| 207R00000X | Internal Medicine | 35090186 (Ohio) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fmc - Na Lakeview Dialysis | Chicago, IL | Dialysis facility |
| Nephron Dialysis Center, Ltd. | Chicago, IL | Dialysis facility |
| Fmc - Neomedica - North Kilpatrick | Chicago, IL | Dialysis facility |
| Swedish Covenant Hospital | Chicago, IL | Hospital |
| Thorek Memorial Hospital | Chicago, IL | Hospital |
| Louis A Weiss Memorial Hospital | Chicago, IL | Hospital |
| Northshore University Healthsystem - Evanston Hospital | Evanston, IL | Hospital |
| Advocate Illinois Masonic Medical Center | Chicago, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Associates In Nephrology Sc | 9133023963 | 51 |
News Archive
CVRx, Inc. announced today the four-year Rheos clinical results from the European study evaluating the Rheos System at the European Society of Hypertension 20th Meeting. The system is the first device designed to treat hypertension (high blood pressure), a leading cause of heart and kidney disease, stroke and death. This device is a future treatment option for the millions of people who cannot control their blood pressure with medications.
News outlets report on a patient's struggle to get coverage for cancer treatment and over-burdened charity clinics.
Today's headlines detail new Congressional Budget Office health law estimates that reflect the Supreme Court's decision on the Medicaid expansion.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration
Many men survive prostate cancer, but thousands of others - whose cancer spreads - inevitably develop resistance to even the most promising treatments, leaving them with few medical options and a dwindling span of life.
› Verified 1 days ago
| Entity Name | Associates In Nephrology Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184694259 PECOS PAC ID: 9133023963 Enrollment ID: O20031124000308 |
News Archive
CVRx, Inc. announced today the four-year Rheos clinical results from the European study evaluating the Rheos System at the European Society of Hypertension 20th Meeting. The system is the first device designed to treat hypertension (high blood pressure), a leading cause of heart and kidney disease, stroke and death. This device is a future treatment option for the millions of people who cannot control their blood pressure with medications.
News outlets report on a patient's struggle to get coverage for cancer treatment and over-burdened charity clinics.
Today's headlines detail new Congressional Budget Office health law estimates that reflect the Supreme Court's decision on the Medicaid expansion.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration
Many men survive prostate cancer, but thousands of others - whose cancer spreads - inevitably develop resistance to even the most promising treatments, leaving them with few medical options and a dwindling span of life.
› Verified 1 days ago
| Entity Name | Mercy Hospital & Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215914791 PECOS PAC ID: 7618861105 Enrollment ID: O20040216000053 |
News Archive
CVRx, Inc. announced today the four-year Rheos clinical results from the European study evaluating the Rheos System at the European Society of Hypertension 20th Meeting. The system is the first device designed to treat hypertension (high blood pressure), a leading cause of heart and kidney disease, stroke and death. This device is a future treatment option for the millions of people who cannot control their blood pressure with medications.
News outlets report on a patient's struggle to get coverage for cancer treatment and over-burdened charity clinics.
Today's headlines detail new Congressional Budget Office health law estimates that reflect the Supreme Court's decision on the Medicaid expansion.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration
Many men survive prostate cancer, but thousands of others - whose cancer spreads - inevitably develop resistance to even the most promising treatments, leaving them with few medical options and a dwindling span of life.
› Verified 1 days ago
| Entity Name | Resilience Healthcare - Lakefront Medical Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205301926 PECOS PAC ID: 5991046468 Enrollment ID: O20190410000827 |
News Archive
CVRx, Inc. announced today the four-year Rheos clinical results from the European study evaluating the Rheos System at the European Society of Hypertension 20th Meeting. The system is the first device designed to treat hypertension (high blood pressure), a leading cause of heart and kidney disease, stroke and death. This device is a future treatment option for the millions of people who cannot control their blood pressure with medications.
News outlets report on a patient's struggle to get coverage for cancer treatment and over-burdened charity clinics.
Today's headlines detail new Congressional Budget Office health law estimates that reflect the Supreme Court's decision on the Medicaid expansion.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration
Many men survive prostate cancer, but thousands of others - whose cancer spreads - inevitably develop resistance to even the most promising treatments, leaving them with few medical options and a dwindling span of life.
› Verified 1 days ago
| Entity Name | Insight Chicago Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881261006 PECOS PAC ID: 2860894706 Enrollment ID: O20210714002059 |
News Archive
CVRx, Inc. announced today the four-year Rheos clinical results from the European study evaluating the Rheos System at the European Society of Hypertension 20th Meeting. The system is the first device designed to treat hypertension (high blood pressure), a leading cause of heart and kidney disease, stroke and death. This device is a future treatment option for the millions of people who cannot control their blood pressure with medications.
News outlets report on a patient's struggle to get coverage for cancer treatment and over-burdened charity clinics.
Today's headlines detail new Congressional Budget Office health law estimates that reflect the Supreme Court's decision on the Medicaid expansion.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration
Many men survive prostate cancer, but thousands of others - whose cancer spreads - inevitably develop resistance to even the most promising treatments, leaving them with few medical options and a dwindling span of life.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Veeda O Landeras, MD 210 S Des Plaines St, Chicago, IL 60661-5500 Ph: (312) 654-2700 | Veeda O Landeras, MD 2740 W Foster Ave Ste 207, Chicago, IL 60625-3526 Ph: (773) 820-8502 |
News Archive
CVRx, Inc. announced today the four-year Rheos clinical results from the European study evaluating the Rheos System at the European Society of Hypertension 20th Meeting. The system is the first device designed to treat hypertension (high blood pressure), a leading cause of heart and kidney disease, stroke and death. This device is a future treatment option for the millions of people who cannot control their blood pressure with medications.
News outlets report on a patient's struggle to get coverage for cancer treatment and over-burdened charity clinics.
Today's headlines detail new Congressional Budget Office health law estimates that reflect the Supreme Court's decision on the Medicaid expansion.
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration
Many men survive prostate cancer, but thousands of others - whose cancer spreads - inevitably develop resistance to even the most promising treatments, leaving them with few medical options and a dwindling span of life.
› Verified 1 days ago
Dr. Sorin C Danciu, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3134 N Clark St, Chicago, IL 60657 Phone: 773-880-9722 | |
Anoopa A. Koshy, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 259 E Erie St Ste 2200, Chicago, IL 60611 Phone: 312-926-6000 | |
William Edmond Gerardi, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 3730 N Lake Shore Dr, Apartment 2a, Chicago, IL 60613 Phone: 773-244-3060 | |
Suparna Dutta, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1700 W Van Buren St, Suite 500, Chicago, IL 60612 Phone: 312-942-4200 Fax: 312-942-3568 | |
Alexandra Dumitrescu, Nephrology Medicare: Accepting Medicare Assignments Practice Location: 5841 S Maryland Ave, Chicago, IL 60637 Phone: 888-824-0200 | |
Dr. Mitesh Mahesh Kabadi, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St Ste 1159, Chicago, IL 60612 Phone: 312-942-5020 | |
Dr. Marta Batus, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St, Suite 809, Chicago, IL 60612 Phone: 312-563-2487 Fax: 312-942-3192 |